ESR1 and neoplasm: Indeed, we found that mutations were very infrequently detected in metastatic samples collected before AI therapy, but were common in patients where tissue was collected after the initiation of AI therapy, supporting the notion that these particular ESR1 mutations arise in the setting of AI exposure as a means of conferring ligand-independent oestrogen receptor signalling to tumour cells.